Search
Browse By Day
Browse By Time
Browse By Person
Browse By Policy Area
Browse By Session Type
Browse By Keyword
Browse Artificial Intelligence Presentations
Program Calendar
Sign In
Search Tips
Introduction/Background: Medicaid Section 1115 substance use disorder (SUD) waivers allow states to use federal funds to cover residential treatment for SUD in institutions for mental diseases, and have the potential to improve the quality of care for people with substance use disorders. Although approved under a common federal framework, states have discretion over key policy components. As a result, there is no single “SUD waiver,” but rather multiple state-specific versions that may differ modestly or substantially in their design. Despite this heterogeneity, waivers are often analyzed as a binary policy exposure, which may obscure meaningful differences and result in biased effect estimates. Legal epidemiology provides a systematic approach to measuring law and policy and can improve the precision of the policy exposure.
Purpose/Research Question: This study applies legal epidemiology to characterize variation in Medicaid SUD waivers across 29 U.S. jurisdictions. Specifically, we ask: how do waiver design and implementation features vary across jurisdictions, and what are the implications of this variation for measuring policy exposure?
Data: We constructed a longitudinal dataset of waiver characteristics across 29 U.S. jurisdictions with approved SUD waivers between 2015 and 2020. Data sources included waiver applications, special terms and conditions, amendments, and implementation protocols obtained from the CMS Medicaid waiver repository.
Research Design and Methods: We conducted a policy surveillance study using a standardized, reproducible protocol to identify, collect, and code relevant documents. A structured coding instrument captured key policy domains, including service coverage, care coordination, requirements for use of medications for opioid use disorder (MOUD), and implementation protocol. Data collection and coding were conducted using a web-based legal epidemiology platform that supports structured questionnaires, document management, and audit trails. Two trained researchers independently coded all documents, with discrepancies resolved through consensus, and all entries verified against primary source materials.
Results/Findings: Substantial heterogeneity was observed in waiver design. While all jurisdictions covered residential treatment and withdrawal management, some jurisdictions expanded coverage to include additional services, including peer recovery support (n=12), case management (n=8), and opioid treatment programs (n=6). MOUD was explicitly included as a covered service in most (n=19), but not all, jurisdictions. Nearly all jurisdictions (n=26) had an implementation protocol approved. However, approval of the implementation protocol varied from concurrent with waiver to one year after waiver approval. These protocols established timelines for key requirements, including phased MOUD requirements for residential settings and expectations for care transitions between residential and outpatient care.
Conclusion/Implications: These findings indicate that Medicaid SUD waivers should be measured as multidimensional and time-varying policy exposures rather than binary indicators, as failure to account for variation in design and implementation may introduce bias in policy evaluation studies.